Wells Fargo & Company Avenue Therapeutics, Inc. Transaction History

Wells Fargo & Company

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	BUY	$0.22 - $0.56 $4,401 - $11,202	20,005 Added 41.62%	68,067 $18,000
Q1 2022 May 16, 2022	BUY	$0.22 - $0.96 $5 - $24	26 Added 0.05%	48,062 $23,000
Q3 2021 Nov 15, 2021	BUY	$1.48 - $2.65 $71,031 - $127,184	47,994 Added 114271.43%	48,036 $72,000
Q2 2021 Aug 16, 2021	SELL	$2.41 - $7.11 $8,784 - $25,915	-3,645 Reduced 98.86%	42 $0
Q1 2021 May 13, 2021	SELL	$4.7 - $7.17 $59,779 - $91,195	-12,719 Reduced 77.53%	3,687 $22,000
Q4 2020 Feb 09, 2021	SELL	$2.95 - $11.04 $7,372 - $27,588	-2,499 Reduced 13.22%	16,406 $98,000
Q3 2020 Nov 05, 2020	BUY	$9.37 - $12.06 $65,908 - $84,830	7,034 Added 59.25%	18,905 $205,000
Q2 2020 Aug 13, 2020	BUY	$8.29 - $11.47 $98,062 - $135,678	11,829 Added 28164.29%	11,871 $128,000
Q1 2020 May 14, 2020	BUY	$6.44 - $11.32 $270 - $475	42 New	42 $0

Ticker ATXI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 4,127,720
Market Cap $9.25M
Description
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was in...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.